Literature DB >> 11264383

Close but distinct regions of human herpesvirus 8 latency-associated nuclear antigen 1 are responsible for nuclear targeting and binding to human mitotic chromosomes.

T Piolot1, M Tramier, M Coppey, J C Nicolas, V Marechal.   

Abstract

Human herpesvirus 8 is associated with all forms of Kaposi's sarcoma, AIDS-associated body cavity-based lymphomas, and some forms of multicentric Castleman's disease. Herpesvirus 8, like other gammaherpesviruses, can establish a latent infection in which viral genomes are stably maintained as multiple episomes. The latent nuclear antigen (LANA or LNAI) may play an essential role in the stable maintenance of latent episomes, notably by interacting concomitantly with the viral genomes and the metaphase chromosomes, thus ensuring an efficient transmission of the neoduplicated episomes to the daughter cells. To identify the regions responsible for its nuclear and subnuclear localization in interphase and mitotic cells, LNAI and various truncated forms were fused to a variant of green fluorescent protein. This enabled their localization and chromosome binding activity to be studied by low-light-level fluorescence microscopy in living HeLa cells. The results demonstrate that nuclear localization of LNAI is due to a unique signal, which maps between amino acids 24 and 30. Interestingly, this nuclear localization signal closely resembles those identified in EBNA1 from Epstein-Barr virus and herpesvirus papio. A region encompassing amino acids 5 to 22 was further proved to mediate the specific interaction of LNA1 with chromatin during interphase and the chromosomes during mitosis. The presence of putative phosphorylation sites in the chromosome binding sites of LNA1 and EBNA1 suggests that their activity may be regulated by specific cellular kinases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11264383      PMCID: PMC114885          DOI: 10.1128/JVI.75.8.3948-3959.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

Review 1.  EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus.

Authors:  E R Leight; B Sugden
Journal:  Rev Med Virol       Date:  2000 Mar-Apr       Impact factor: 6.989

2.  p53 inhibition by the LANA protein of KSHV protects against cell death.

Authors:  J Friborg; W Kong; M O Hottiger; G J Nabel
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

3.  Human herpesvirus 8 and Epstein Barr-virus in a cutaneous B-cell lymphoma and a malignant cell line established from the blood of an AIDS patient.

Authors:  P Morand; M Buisson; H Collandre; B Chanzy; O Genoulaz; M J Bourgeat; N Pinel; P Leclercq; D Leroux; V Marechal; L Fritsch; R Ruigrok; J M Seigneurin
Journal:  Leuk Lymphoma       Date:  1999-10

4.  Hot-spot variations of Kaposi's sarcoma-associated herpesvirus latent nuclear antigen and application in genotyping by PCR-RFLP.

Authors:  Yan-Jin Zhang; Jian-Hong Deng; Charles Rabkin; Shou-Jiang Gao
Journal:  J Gen Virol       Date:  2000-08       Impact factor: 3.891

5.  Human herpesvirus-8-encoded LNA-1 accumulates in heterochromatin- associated nuclear bodies.

Authors:  Laszlo Szekely; Csaba Kiss; Karin Mattsson; Elena Kashuba; Katja Pokrovskaja; Attila Juhasz; Pia Holmvall; George Klein
Journal:  J Gen Virol       Date:  1999-11       Impact factor: 3.891

6.  HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma.

Authors:  N Dupin; T L Diss; P Kellam; M Tulliez; M Q Du; D Sicard; R A Weiss; P G Isaacson; C Boshoff
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

7.  The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells.

Authors:  M A Cotter; E S Robertson
Journal:  Virology       Date:  1999-11-25       Impact factor: 3.616

8.  Proteasome-mediated degradation of the papillomavirus E2-TA protein is regulated by phosphorylation and can modulate viral genome copy number.

Authors:  K J Penrose; A A McBride
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

9.  Molecular polymorphism of Kaposi's sarcoma-associated herpesvirus (Human herpesvirus 8) latent nuclear antigen: evidence for a large repertoire of viral genotypes and dual infection with different viral genotypes.

Authors:  S J Gao; Y J Zhang; J H Deng; C S Rabkin; O Flore; H B Jenson
Journal:  J Infect Dis       Date:  1999-11       Impact factor: 5.226

10.  Identification of a spliced gene from Kaposi's sarcoma-associated herpesvirus encoding a protein with similarities to latent membrane proteins 1 and 2A of Epstein-Barr virus.

Authors:  M Glenn; L Rainbow; F Auradé; A Davison; T F Schulz
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

View more
  99 in total

1.  The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus supports latent DNA replication in dividing cells.

Authors:  Jianhong Hu; Alexander C Garber; Rolf Renne
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  Protein interactions targeting the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus to cell chromosomes.

Authors:  Anita Krithivas; Masahiro Fujimuro; Magdalena Weidner; David B Young; S Diane Hayward
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Chromosome binding site of latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus is essential for persistent episome maintenance and is functionally replaced by histone H1.

Authors:  Hirohiko Shinohara; Masaya Fukushi; Masaya Higuchi; Masayasu Oie; Osamu Hoshi; Tatsuo Ushiki; Jun-Ichi Hayashi; Masahiro Fujii
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen prolongs the life span of primary human umbilical vein endothelial cells.

Authors:  Takahiro Watanabe; Makoto Sugaya; April M Atkins; Elisabeth A Aquilino; Aparche Yang; Debra L Borris; John Brady; Andrew Blauvelt
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

5.  Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis.

Authors:  Adam Grundhoff; Don Ganem
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

6.  The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus permits replication of terminal repeat-containing plasmids.

Authors:  Adam Grundhoff; Don Ganem
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

7.  Visualization of a functional KSHV episome-maintenance protein LANA in living cells.

Authors:  Takafumi Tetsuka; Masaya Higuchi; Masaya Fukushi; Akiko Watanabe; Sayoko Takizawa; Masayasu Oie; Fumitake Gejyo; Masahiro Fujii
Journal:  Virus Genes       Date:  2004-10       Impact factor: 2.332

8.  Accumulation of heterochromatin components on the terminal repeat sequence of Kaposi's sarcoma-associated herpesvirus mediated by the latency-associated nuclear antigen.

Authors:  Shuhei Sakakibara; Keiji Ueda; Ken Nishimura; Eunju Do; Eriko Ohsaki; Toshiomi Okuno; Koichi Yamanishi
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

9.  Protein arginine methyltransferase 1-directed methylation of Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen.

Authors:  Mel Campbell; Pei-Ching Chang; Steve Huerta; Chie Izumiya; Ryan Davis; Clifford G Tepper; Kevin Y Kim; Bogdan Shevchenko; Don-Hong Wang; Jae U Jung; Paul A Luciw; Hsing-Jien Kung; Yoshihiro Izumiya
Journal:  J Biol Chem       Date:  2011-12-16       Impact factor: 5.157

10.  Functional dissection of latency-associated nuclear antigen 1 of Kaposi's sarcoma-associated herpesvirus involved in latent DNA replication and transcription of terminal repeats of the viral genome.

Authors:  Chunghun Lim; Hekwang Sohn; Daeyoup Lee; Yousang Gwack; Joonho Choe
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.